| Aggregate Evidence Quality . | Grade B . |
|---|---|
| Benefits | Potential prevention of progressive CVD; regression or avoidance of target organ damage; resolution of hypertensive symptoms; improved cognition; avoidance of worsening HTN; potential avoidance of stroke, heart failure, coronary artery disease, kidney failure |
| Risks, harm, cost | Potential for hypotension, financial cost, chronic medication treatment, adverse medication effects, impact on insurability (health and life) |
| Benefit–harm assessment | Preponderance of benefits over harms |
| Intentional vagueness | None |
| Role of patient preferences | The choice of which antihypertensive medication to use should be made in close discussion with the patient and parent regarding risk, benefits, and adverse effects |
| Exclusions | None |
| Strength | Moderate recommendation |
| Key references | 452,455,467 |
| Aggregate Evidence Quality . | Grade B . |
|---|---|
| Benefits | Potential prevention of progressive CVD; regression or avoidance of target organ damage; resolution of hypertensive symptoms; improved cognition; avoidance of worsening HTN; potential avoidance of stroke, heart failure, coronary artery disease, kidney failure |
| Risks, harm, cost | Potential for hypotension, financial cost, chronic medication treatment, adverse medication effects, impact on insurability (health and life) |
| Benefit–harm assessment | Preponderance of benefits over harms |
| Intentional vagueness | None |
| Role of patient preferences | The choice of which antihypertensive medication to use should be made in close discussion with the patient and parent regarding risk, benefits, and adverse effects |
| Exclusions | None |
| Strength | Moderate recommendation |
| Key references | 452,455,467 |